Skip to main content

Table 2 Association of PD-L1 staining with clinicopathologic factors in all patients with neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

 TCTCICICsTIL level
FactorsNegativePositiveFisherNegativePositiveFisherNegativePositiveFisherLowHighFisher
N (%)N (%)P valueN (%)N (%)P valueN (%)N (%)P valueN (%)N (%)P value
Age[N = 141] [N = 131] [N = 131] [N = 145] 
 < 50 years50 (94)3 (6)0.53545 (88)6 (12)0.165147 (92)4 (8)0.125741 (73)15 (27)0.557
 ≥ 50 years79 (90)9 (10) 62 (78)18 (23) 65 (81)15 (19) 69 (78)20 (22) 
Race/ethnicity[N = 141] [N = 131] [N = 131] [N = 145] 
 Black19 (79)5 (21)0.022818 (75)6 (25)0.512620 (83)4 (17)0.922516 (70)7 (30)0.6991
 White+Latino97 (95)5 (5) 78 (84)15 (16) 80 (86)13 (14) 82 (77)24 (23) 
 Others13 (87)2 (13) 11 (79)3 (21) 12 (86)2 (14) 12 (75)4 (25) 
Histologic type[N = 141] [N = 131] [N = 131] [N = 145] 
 IDC106 (91)10 (9)0.073785 (79)22 (21)0.062489 (83)18 (17)0.250887 (73)33 (28)0.1731
 ILC17 (100)0 (0) 16 (100)0 (0) 16 (100)0 (0) 16 (94)1 (6) 
 Metaplastic3 (60)2 (40) 3 (60)2 (40) 4 (80)1 (20) 4 (80)1 (20) 
 Mixed IDC/ILC3 (100)0 (0) 3 (100)0 (0) 3 (100)0 (0) 3 (100)0 (0) 
Histologic gradea[N = 141] [N = 131] [N = 131] [N = 145] 
 1 + 268 (100)0 (0)0.000362 (95)3 (5)0.000162 (95)3 (5)0.002265 (88)9 (12)0.0008
 361 (84)12 (16) 45 (68)21 (32) 50 (76)16 (24) 45 (63)26 (37) 
sTIL level[N = 139] [N = 131] [N = 131] NA 
 < 10%102 (97)3 (3)0.000289 (91)9 (9)< 0.000190 (92)8 (8)0.0006   
 ≥ 10%25 (74)9 (26) 16 (52)15 (48) 20 (65)11 (35)    
ER[N = 141] [N = 131] [N = 131] [N = 145] 
 Negative30 (77)9 (23)0.000520 (57)15 (43)< 0.000124 (69)11 (31)0.001922 (56)17 (44)0.0018
 Positive99 (97)3 (3) 87 (91)9 (9) 88 (92)8 (8) 88 (83)18 (17) 
PR[N = 141] [N = 131] [N = 131] [N = 145] 
 Negative48 (83)10 (17)0.003734 (67)17 (33)0.000939 (76)12 (24)0.023636 (62)22 (38)0.0026
 Positive81 (98)2 (2) 73 (91)7 (9) 73 (91)7 (9) 74 (85)13 (15) 
HER2[N = 141] [N = 131] [N = 131] [N = 145] 
 Negative118 (91)12 (9)0.598798(81)23 (19)0.6881103 (85)18 (15)199 (75)33 (25)0.7344
 Positive11 (100)0 (0) 9(90)1 (10) 9 (90)1 (10) 11 (85)2 (15) 
TNBC[N = 141] [N = 131] [N = 131] [N = 145] 
 No101 (97)3 (3)0.000388 (91)9 (9)< 0.000189 (92)8 (8)0.001490 (83)18 (17)0.0007
 Yes28 (76)9 (24) 19 (56)15 (44) 23 (68)11 (32) 20 (54)17 (46) 
Receptor group[N = 141] [N = 131] [N = 131] [N = 145] 
 ER/PR pos90 (97)3 (3)0.001279 (91)8 (9)0.000180 (92)7 (8)0.003879 (83)16 (17)0.0023
 HER211 (100)0 (0) 9 (90)1 (10) 9 (90)1 (10) 11 (85)2 (15) 
 TNBC28 (76)9 (24) 19 (56)15 (44) 23 (68)11 (32) 20 (54)17 (46) 
Tumor size[N = 141] [N = 131] [N = 131] [N = 145] 
 ≤ 2 cm26 (84)5 (16)0.243319 (73)7 (27)0.428620 (77)6 (23)0.376521 (62)13 (38)0.049
 > 2 to 5 cm54 (93)4 (7) 49 (84)9 (16) 51 (88)7 (12) 43 (75)14 (25) 
 > 5 cm49 (94)3 (6) 39 (83)8 (17) 41 (87)6 (13) 46 (85)8 (15) 
ypN[N = 141] [N = 131] [N = 131] [N = 145] 
 (y)pN039 (85)7 (15)0.092133 (77)10 (23)0.624736 (84)7 (16)0.942435 (74)12 (26)0.3048
 (y)pN145 (96)2 (4) 36 (84)7 (16) 36 (84)7 (16) 37 (74)13 (26) 
 (y)pN222 (88)3 (12) 19 (79)5 (21) 21 (88)3 (13) 18 (69)8 (31) 
 (y)pN323 (100)0 (0) 19 (90)2 (10) 19 (90)2 (10) 20 (91)2 (9) 
pM[N = 141] [N = 131] [N = 131] [N = 145] 
 0119 (91)12 (9)1101 (82)22 (18)0.6382106 (86)17 (14)0.3272100 (74)35 (26)0.1184
 110 (100)0 (0) 6 (75)2 (25) 6 (75)2 (25) 10 (100)0 (0) 
RCB category[N = 140] [N = 130] [N = 130] [N = 144] 
 I4 (80)1 (20)0.51553 (75)1 (25)0.41253 (75)1 (25)0.24735 (83)1 (17)0.9425
 II63 (91)6 (9) 54 (86)9 (14) 57 (90)6 (10) 56 (77)17 (23) 
 III61 (92)5 (8) 49 (78)14 (22) 51 (81)12 (19) 48 (74)17 (26) 
  1. aHistologic grade for post-treatment tumors was based on pre-treatment grade
  2. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, sTIL stromal tumor infiltrating lymphocytes, ER estrogen receptor, PR progesterone receptor, TNBC triple-negative breast cancer, pos positive, RCB residual cancer burden